464 related articles for article (PubMed ID: 27013513)
1. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
Dolling DI; Desai M; McOwan A; Gilson R; Clarke A; Fisher M; Schembri G; Sullivan AK; Mackie N; Reeves I; Portman M; Saunders J; Fox J; Bayley J; Brady M; Bowman C; Lacey CJ; Taylor S; White D; Antonucci S; Gafos M; McCormack S; Gill ON; Dunn DT; Nardone A;
Trials; 2016 Mar; 17():163. PubMed ID: 27013513
[TBL] [Abstract][Full Text] [Related]
2. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S; Dunn DT; Desai M; Dolling DI; Gafos M; Gilson R; Sullivan AK; Clarke A; Reeves I; Schembri G; Mackie N; Bowman C; Lacey CJ; Apea V; Brady M; Fox J; Taylor S; Antonucci S; Khoo SH; Rooney J; Nardone A; Fisher M; McOwan A; Phillips AN; Johnson AM; Gazzard B; Gill ON
Lancet; 2016 Jan; 387(10013):53-60. PubMed ID: 26364263
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
4. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
5. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
6. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
[TBL] [Abstract][Full Text] [Related]
7. Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants.
O'Halloran C; Rice B; White E; Desai M; Dunn DT; McCormack S; Sullivan AK; White D; McOwan A; Gafos M
Int J Drug Policy; 2019 Dec; 74():246-254. PubMed ID: 31739177
[TBL] [Abstract][Full Text] [Related]
8. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
[TBL] [Abstract][Full Text] [Related]
9. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
Sullivan AK; Saunders J; Desai M; Cartier A; Mitchell HD; Jaffer S; Ogaz D; Chiavenna C; Charlett A; Diamente V; Golombek R; Manavi K; Priestley C; Waters LJ; Milinkovic A; McOwan A; Estcourt C; Sabin CA; Rodger A; Gold D; Gazzard BG; McCormack S; Gill ON;
Lancet HIV; 2023 Dec; 10(12):e790-e806. PubMed ID: 38040478
[TBL] [Abstract][Full Text] [Related]
10. Trends in HIV incidence between 2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study.
Hanum N; Cambiano V; Sewell J; Rodger AJ; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Delpech V; Croxford S; Phillips AN; Lampe FC;
PLoS Med; 2021 Jun; 18(6):e1003677. PubMed ID: 34143781
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.
White E; Dunn DT; Desai M; Gafos M; Kirwan P; Sullivan AK; Clarke A; McCormack S;
Sex Transm Infect; 2019 Sep; 95(6):449-454. PubMed ID: 30918121
[TBL] [Abstract][Full Text] [Related]
12. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.
Hoornenborg E; Coyer L; Achterbergh RCA; Matser A; Schim van der Loeff MF; Boyd A; van Duijnhoven YTHP; Bruisten S; Oostvogel P; Davidovich U; Hogewoning A; Prins M; de Vries HJC;
Lancet HIV; 2019 Jul; 6(7):e447-e455. PubMed ID: 31178284
[TBL] [Abstract][Full Text] [Related]
13. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
[TBL] [Abstract][Full Text] [Related]
14. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
15. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
16. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study.
Hanum N; Cambiano V; Sewell J; Phillips AN; Rodger AJ; Speakman A; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Lampe FC;
Lancet Public Health; 2020 Sep; 5(9):e501-e511. PubMed ID: 32888443
[TBL] [Abstract][Full Text] [Related]
17. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): Four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort.
van den Elshout MAM; Wijstma ES; Boyd A; Jongen VW; Coyer L; Anderson PL; Davidovich U; de Vries HJC; Prins M; Schim van der Loeff MF; Hoornenborg E;
PLoS Med; 2024 May; 21(5):e1004328. PubMed ID: 38718068
[TBL] [Abstract][Full Text] [Related]
18. Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England.
Mitchell HD; Desai S; Mohammed H; Ong KJ; Furegato M; Hall V; Desai M; Saunders JM; Hughes G; Field N; Gill ON
Sex Transm Infect; 2019 Nov; 95(7):484-487. PubMed ID: 31010953
[TBL] [Abstract][Full Text] [Related]
19. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
